Recovery article

How Much Does a Thymosin Alpha-1 Cycle Cost? (2026 Calculato

How Much Does a Thymosin Alpha-1 Cycle Cost? Pick your protocol and duration — we'll show you how many vials you need and the total cost from 7 vendors. Quick Answer A 8-week standard immune boost (8 weeks) cycle starts at $213.00 6 vials from Ascension Peptid

By Recovery & Performance Peptides Editorial Team Published July 15, 2026

How Much Does a Thymosin Alpha-1 Cycle Cost?

Pick your protocol and duration — we'll show you how many vials you need and the total cost from 7 vendors.

Quick Answer

A 8-week standard immune boost (8 weeks) cycle starts at $213.00

6 vials from Ascension Peptides at $71.00 per vial

What Dose and Duration Are You Running?

Which Vendor Is the Best Deal for This Cycle?(7 vendors)

Best Thymosin Alpha-1 Vendors of 2026 →

Ranked by price, purity testing, and buyer trust

Best Deal on Thymosin Alpha-1 →

All vendors sorted by $/mg — find the best deal

Best LL-37 Vendors of 2026 →

Calculate the Cost of Your LL-37 Cycle →

Pick your dose and duration — see the total with supplies

Disclaimer: This calculator is for informational purposes only. Prices are updated regularly but may change. These peptides are sold for research purposes only and are not intended for human consumption. Always consult a healthcare provider before starting any research protocol.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

COACH'S BOARD / KEY POINTS

Thymosin alpha-1 requires reconstitution with bacteriostatic water at a 3.2mg/mL concentration to match clinical trial dosing, and remains stable for 28 days at 2–8°C before oxidative degradation reduces potency.
The standard protocol uses 1.6mg injected subcutaneously twice weekly (every 3–4 days) for 8–16 weeks. Daily dosing doesn't improve immune outcomes because T-cell receptor upregulation doesn't accelerate with more frequent administration.
Injection site rotation across abdomen, thigh, and upper arm prevents lipohypertrophy, which reduces peptide absorption by 30–40% when the same site is reused within 10 days.
Clinical immune trials measure CD4+ T-cell count, natural killer cell activity, and interleukin-2 production at baseline, week 4, week 8, and 2 weeks post-cycle to confirm protocol effectiveness.
Thymosin alpha-1 should be injected at least 4 hours separated from GHRPs or CJC-1295 to prevent receptor competition that reduces efficacy of both peptide classes.

SOURCE / realpeptides.co ↗

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Future research

Peptides have huge therapeutic value. Significant research has taken place over the years. It has successfully treated a wide range of diseases. It’s also used in aesthetic treatments. Many people feel comfortable in using this safe and natural approach to their health. There’s great potential for this market to increase. Investments into this area of research seem positive. Continuous support from the government and investors can increase COVID research. With the success of this treatment, there’s a need to make more of them available. Phase 3 trial in hepatitis C is still in progress. The same applies to phase 2 in hepatitis B. There are also efforts underway to improve oral availability. To make it more permeable for the GI tract.